Skandinaviska Enskilda Banken AB publ grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 148.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,817,880 shares of the biopharmaceutical company's stock after purchasing an additional 1,085,987 shares during the quarter. Gilead Sciences makes up approximately 0.8% of Skandinaviska Enskilda Banken AB publ's portfolio, making the stock its 25th largest holding. Skandinaviska Enskilda Banken AB publ owned 0.15% of Gilead Sciences worth $167,209,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of GILD. Avior Wealth Management LLC increased its holdings in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Southland Equity Partners LLC lifted its holdings in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after purchasing an additional 110 shares in the last quarter. Concord Asset Management LLC VA lifted its stake in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock worth $256,000 after purchasing an additional 111 shares in the last quarter. Berkshire Bank grew its holdings in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 111 shares in the last quarter. Finally, GHP Investment Advisors Inc. increased its position in Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 122 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 311,285 shares of company stock valued at $31,284,910. 0.16% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday. Citigroup assumed coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target for the company. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.52.
Get Our Latest Report on GILD
Gilead Sciences Stock Down 0.4 %
Shares of NASDAQ:GILD opened at $113.99 on Thursday. The stock has a market capitalization of $141.96 billion, a P/E ratio of 308.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50-day moving average price is $100.99 and its 200-day moving average price is $92.33. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.77%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is presently 854.05%.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
